The EPS beat is entirely from non-dilutive collaboration revenue, not operational improvement, ignore for valuation. The key catalyst is SEP-479 SAD/MAD data in Q1 2027; binary event for hypoparathyroidism thesis. Monitor SEP-631 Phase 2 strategy update and TSHR candidate selection as next catalysts.
Drugs in focus
SEPN drug pipeline →SEP-479
● Neutral Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $47.76entry
- T+1 · 3mo ago +0.90%α +0.65% · $48.19
- T+5 · 3mo ago −8.29%α −7.89% · $43.80
- T+20 · 2mo ago −20.50%α −19.44% · $37.97
- T+60 · 13d ago +0.25%α +0.74% · $47.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39.6% beat. Pipeline progress was steady: SEP-479 Phase 1 PK supports once-daily dosing with SAD/MAD data expected Q1 2027; SEP-631 Phase 1 data positive; TSHR NAM advancing toward candidate selection. Cash of $516.5M funds operations into 2029. Collaboration revenue of $26.7M from Novo Nordisk drove the beat, but as a clinical-stage biotech this is non-core milestone/amortization revenue, the EPS surprise is mechanical, not growth-driven.
Key Financial Metrics
Key Facts
- Net loss was $13.0M for Q2 2026 vs $24.8M in Q2 2025; EPS -$0.29 vs consensus -$0.48 (beat).
- Revenue of $26.7M from Novo Nordisk collaboration (amortization of $14.6M upfront + $0.9M milestones + $11.2M research services).
- SEP-479 Phase 1 ongoing; observed half-life ~3–4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 Phase 1 results reported March 2026: well-tolerated, once-daily PK, robust skin wheal suppression; evaluating Phase 2 strategies.
- TSHR NAM program progressing toward development candidate selection for Graves' disease / thyroid eye disease.
- Cash position $516.5M; expected runway into 2029.
- R&D expenses $35.1M (up 58% YoY) and G&A $8.5M (up 23% YoY) reflecting clinical ramp.
Financial Impact
EPS beat of $0.19 vs $0.48 consensus (39.6%) driven by Novo Nordisk collaboration revenue, non-core to pipeline valuation. Cash burn rate ~$18M/quarter implies 7+ years runway.
Risk Factors
- SEP-479 Phase 1 data delayed to Q1 2027; MAD cohort extension may increase development timeline risk.
- SEP-631 Phase 2 strategy undefined, potential for pivot or failure in mast cell-driven diseases.
- Pre-revenue clinical-stage biotech with no approved products; valuation tied entirely to pipeline milestones.
- R&D spend increasing 58% YoY with no near-term revenue growth from non-collaboration sources.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342181 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers